文献速递肝病

RAS抑制剂与钙通道阻滞剂对MASLD肝硬度动态及长期肝脏事件的影响

Associations of RAS inhibitors and Calcium Channel Blockers with Liver Stiffness Dynamics and Long-term Liver-Related Events in MASLD.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-10-06

基于VCTE-Prognosis国际多中心队列4302例MASLD合并高血压患者,中位随访4.6年,采用IPTW加权的Cox模型分析。RASi使用与肝硬度消退(HR=1.220)及较低长期肝脏事件风险(HR=0.431)相关;CCB使用与肝硬度进展风险降低(HR=0.681)及较低肝脏事件风险(HR=0.559)相关。

要点

  • RASi使用与肝硬度消退可能性更高及长期肝脏事件风险更低相关。
  • CCB使用与肝硬度进展风险更低及长期肝脏事件风险更低相关。
  • 两类降压药对肝硬度动态的影响方向不同,但均与较低肝脏事件风险相关。

核心结论

  • 在MASLD合并高血压患者中,RASi和CCB使用均与有利的肝硬度轨迹及较低的长期肝脏相关事件风险相关。

研究设计与样本

  • 基于VCTE-Prognosis国际多中心队列,纳入4302例MASLD合并高血压患者,中位随访4.6年。
  • 采用Cox比例风险模型结合逆概率治疗加权(IPTW),比较RASi使用者与非使用者、CCB使用者与非使用者。

主要发现

  • RASi使用与肝硬度消退可能性更高相关(HR=1.220,95%CI 1.010-1.474;P=0.039),对肝硬度进展无显著影响。
  • RASi使用与长期肝脏事件风险降低相关(HR=0.431,95%CI 0.261-0.714;P=0.001)。
  • CCB使用与肝硬度进展风险降低相关(HR=0.681,95%CI 0.521-0.890;P=0.005),与肝硬度消退无显著相关。
  • CCB使用与肝脏事件风险降低相关(HR=0.559,95%CI 0.326-0.958;P=0.034)。
  • 亚组和敏感性分析结果一致。

关键数值与推荐

  • 肝硬度进展定义为较基线增加≥20%及Baveno分类升级。
  • 肝硬度消退定义为较基线降低≥20%及Baveno分类降级。
  • RASi使用者占41.2%,CCB使用者占32.0%。

临床怎么用

  • 对于MASLD合并高血压患者,选择RASi或CCB可能对肝硬度轨迹和长期肝脏事件风险产生有利影响。
  • 临床决策时可结合患者肝硬度动态及肝脏事件风险,考虑优先选用RASi或CCB。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypertension is common in metabolic dysfunction-associated steatotic liver disease (MASLD), but the effects of specific antihypertensive drug classes on liver stiffness and liver-related events (LREs) remain unclear. AIMS: We evaluated associations of renin-angiotensin system inhibitors (RASi) and calcium channel blockers (CCBs) with changes in liver stiffness and with long-term LRE risk. DESIGN: We analyzed data from the VCTE-Prognosis cohort, an international multicenter study with serial liver stiffness measurements. Outcomes included liver stiffness progression (≥20% increase and Baveno category upshift), liver stiffness regression (≥20% decrease and Baveno category downshift), and incident LREs. We assessed associations between baseline antihypertensive therapy and liver outcomes using Cox proportional hazards models with inverse probability of treatment weighting, comparing RASi users versus non-users and CCB users versus non-users. RESULTS: We followed 4,302 individuals with MASLD and hypertension for a median of 4.6 years, of whom 41.2% received RASi and 32.0% received CCBs. RASi use was associated with a higher likelihood of liver stiffness regression (HR=1.220, 95%CI 1.010-1.474; P=0.039) and associated with a lower risk of long-term LREs (HR=0.431, 95%CI 0.261-0.714; P=0.001), with no significant effect on liver stiffness progression. Conversely, CCB use was associated with a lower risk of liver stiffness progression (HR=0.681, 95%CI 0.521-0.890; P=0.005) and LREs (HR=0.559, 95%CI 0.326-0.958; P=0.034), but not with liver stiffness regression. Findings were consistent across subgroup and sensitivity analyses. CONCLUSION: RASi and CCB use were associated with favorable liver stiffness trajectories and lower risk of long-term liver-related events in individuals with MASLD and hypertension.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Zhou XD, Chen QF, Kim SU, et al. Associations of RAS inhibitors and Calcium Channel Blockers with Liver Stiffness Dynamics and Long-term Liver-Related Events in MASLD. Clin Gastroenterol Hepatol. 2026. PMID: 42838311. doi:10.1016/j.cgh.2026.09.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。